IDEXX LABORATORIES, INC. Financials IDEXX Laboratories, Inc.
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 509.4 USD | +2.38% |
|
+3.52% | -8.16% |
| May. 29 | Transcript : IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference, May-29-2024 10:55 AM | |
| May. 14 | Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,400 | 42,639 | 55,833 | 33,786 | 46,098 | 41,088 | - | - |
| Enterprise Value (EV) 1 | 23,298 | 43,163 | 56,612 | 35,022 | 46,592 | 41,484 | 41,311 | 40,994 |
| P/E ratio | 53.4 x | 74.5 x | 76.6 x | 50.8 x | 55.2 x | 44.9 x | 39.8 x | 34.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.31 x | 15.8 x | 17.4 x | 10 x | 12.6 x | 10.4 x | 9.47 x | 8.6 x |
| EV / Revenue | 9.68 x | 15.9 x | 17.6 x | 10.4 x | 12.7 x | 10.5 x | 9.52 x | 8.58 x |
| EV / EBITDA | 36.4 x | 54.6 x | 54.6 x | 34.7 x | 38.4 x | 31.3 x | 28 x | 25.2 x |
| EV / FCF | 76.6 x | 79.8 x | 89 x | 88.9 x | 60.3 x | 46.9 x | 42 x | 38.4 x |
| FCF Yield | 1.31% | 1.25% | 1.12% | 1.13% | 1.66% | 2.13% | 2.38% | 2.61% |
| Price to Book | 127 x | 67.5 x | 82.6 x | 55.6 x | 31 x | 22.2 x | 15.9 x | 11.7 x |
| Nbr of stocks (in thousands) | 85,783 | 85,300 | 84,794 | 82,817 | 83,052 | 82,587 | - | - |
| Reference price 2 | 261.1 | 499.9 | 658.5 | 408.0 | 555.0 | 497.5 | 497.5 | 497.5 |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 | 3,944 | 4,339 | 4,777 |
| EBITDA 1 | 640.9 | 790.5 | 1,037 | 1,011 | 1,212 | 1,325 | 1,477 | 1,625 |
| EBIT 1 | 552.8 | 694.5 | 932 | 898.8 | 1,097 | 1,203 | 1,348 | 1,514 |
| Operating Margin | 22.97% | 25.66% | 28.99% | 26.69% | 29.97% | 30.5% | 31.06% | 31.68% |
| Earnings before Tax (EBT) 1 | 522.2 | 662 | 902.7 | 860 | 1,061 | 1,173 | 1,307 | 1,470 |
| Net income 1 | 427.7 | 581.8 | 744.8 | 679.1 | 845 | 922.3 | 1,036 | 1,167 |
| Net margin | 17.77% | 21.49% | 23.17% | 20.17% | 23.08% | 23.38% | 23.87% | 24.43% |
| EPS 2 | 4.890 | 6.710 | 8.600 | 8.030 | 10.06 | 11.07 | 12.51 | 14.31 |
| Free Cash Flow 1 | 304.2 | 541.1 | 636 | 394.1 | 772.9 | 884.8 | 982.7 | 1,068 |
| FCF margin | 12.64% | 19.99% | 19.78% | 11.71% | 21.11% | 22.43% | 22.65% | 22.36% |
| FCF Conversion (EBITDA) | 47.47% | 68.45% | 61.35% | 39% | 63.77% | 66.77% | 66.54% | 65.72% |
| FCF Conversion (Net income) | 71.12% | 93.01% | 85.39% | 58.04% | 91.46% | 95.94% | 94.88% | 91.53% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 801.1 | 836.5 | 860.5 | 841.7 | 828.6 | 900.2 | 943.6 | 915.5 | 901.6 | 964.1 | 1,003 | 991.8 | 979.3 | 1,057 | 1,100 |
| EBITDA 1 | 226.9 | 274.9 | 207.2 | 281.5 | 255.2 | 308.7 | 324 | 304.3 | 275 | 328.9 | 343.6 | 329.9 | 304 | - | - |
| EBIT 1 | 199.2 | 248.3 | 179.1 | 253 | 226.5 | 280.4 | 296.1 | 275.3 | 245.3 | 299 | 316.5 | 305 | 278.9 | 333.6 | 357.6 |
| Operating Margin | 24.86% | 29.69% | 20.81% | 30.06% | 27.34% | 31.15% | 31.38% | 30.07% | 27.21% | 31.01% | 31.55% | 30.75% | 28.48% | 31.57% | 32.52% |
| Earnings before Tax (EBT) 1 | 191.9 | 241.5 | 171.1 | 234.2 | 213.2 | 267.7 | 285.9 | 267.9 | 239.7 | 295.5 | 309.9 | 298.1 | 269.9 | 327.8 | 349.8 |
| Net income 1 | 162.8 | 194 | 132 | 180.9 | 172.2 | 214.1 | 224.2 | 212.2 | 194.5 | 235.6 | 240.2 | 232.1 | 212.8 | 261.5 | 273.8 |
| Net margin | 20.32% | 23.19% | 15.34% | 21.5% | 20.78% | 23.78% | 23.76% | 23.18% | 21.58% | 24.44% | 23.94% | 23.41% | 21.73% | 24.75% | 24.9% |
| EPS 2 | 1.890 | 2.270 | 1.560 | 2.150 | 2.050 | 2.550 | 2.670 | 2.530 | 2.320 | 2.810 | 2.893 | 2.796 | 2.597 | 3.145 | 3.300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/2/22 | 5/4/22 | 8/2/22 | 11/1/22 | 2/6/23 | 5/2/23 | 8/1/23 | 11/1/23 | 2/5/24 | 5/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 897 | 525 | 779 | 1,236 | 494 | 396 | 223 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 93.9 |
| Leverage (Debt/EBITDA) | 1.4 x | 0.6636 x | 0.7517 x | 1.223 x | 0.4075 x | 0.2987 x | 0.1509 x | - |
| Free Cash Flow 1 | 304 | 541 | 636 | 394 | 773 | 885 | 983 | 1,068 |
| ROE (net income / shareholders' equity) | 509% | 144% | 113% | 105% | 80.7% | 49.7% | 41.7% | 37.4% |
| ROA (Net income/ Total Assets) | 25.4% | 28.2% | 31.5% | 26.2% | 28.1% | 26.2% | 25.8% | 25.2% |
| Assets 1 | 1,685 | 2,064 | 2,366 | 2,592 | 3,003 | 3,514 | 4,010 | 4,632 |
| Book Value Per Share 2 | 2.060 | 7.410 | 7.970 | 7.340 | 17.90 | 22.40 | 31.30 | 42.50 |
| Cash Flow per Share 2 | 5.250 | 7.470 | 8.730 | 6.420 | 10.80 | 12.80 | 14.00 | 15.90 |
| Capex 1 | 155 | 107 | 120 | 149 | 134 | 179 | 188 | 201 |
| Capex / Sales | 6.44% | 3.95% | 3.72% | 4.42% | 3.65% | 4.54% | 4.34% | 4.22% |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
497.5
USD
Average target price
565.1
USD
Spread / Average Target
+13.58%
EPS Revisions
- Stock Market
- Equities
- IDXX Stock
- Financials IDEXX Laboratories, Inc.
